Back to results
US 7,067,516 B2Granted
Serine protease inhibitors
AssigneeTularik Inc.
InventorsSarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
Claims41
A tryptase inhibitor compound of formula (I)
- where:
- R5 represents amino, hydroxy, aminomethyl, hydroxymethyl or hydrogen;
- R6a represents hydrogen or methyl;
- X—X is selected from the group consisting of —CH═CH—, —CONR1a—, —NH—CO—, —NR1a—CH2—, —CH2—NR1a—, —CH2O—, —OCH2—, —COO—, —OC═O— and —CH2CH2—;
- R1a represents hydrogen, (1–6C)alkyl or phenyl(1–6C)alkyl;
- L is CONR1d(CH2)m in which m is 0 or 1 and R1d is hydrogen, (1–6C)alkyl or phenyl(1–6C)alkyl;
- Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group optionally substituted by one or more groups R3a — or R3iXi—;
- each R3a independently is hydrogen, hydroxyl, (1–6C) alkoxy, (1–6C)alkyl, (2–6C)alkenyl, (2–6C)alkynyl, (1–6C)alkanoyl, (1–6C)alkylaminoalkyl, hydroxy(1–6C)alkyl, carboxy, (1–6C)alkoxyalkyl, (1–6C)alkoxycarbonyl, (1–6C) alkylaminocarbonyl, amino (1–6C)alkyl, CONH2, CH2CONH2, aminoacetyl, (1–6C)alkanoylamino, hydroxy(1–6C) alkanoylamino, amino(1–6C)alkanoylamino, (1–6C)alkylamino(1–6C) alkanoylamino, di(1–6C)alkylamino(1–6C)alkanoylamino, (1–6C) alkoxycarbonylamino, amino, halo, cyano, nitro, thiol, (1–6C) alkylthio, (1–6C) alkylsulphonyl, (1–6C) alkylsulphenyl, imidazolyl, hydrazido, (16C)alkylimidazolyl, (1–6C) alkylsulphonamido, (1–6C) alkylaminosulphonyl, aminosulphonyl, (1–6C) haloalkoxy, or (1–6C)haloalkyl;
- Xi is a bond, O, NR1p, CH2, CO, CONR1p, R1pCO, SO2, NR1pSO2 or SO2NR1p;
- R3i is phenyl or pyridyl;
- R1i is as defined for R1a
- Lp is selected from the group consisting of
- in which R3 is an amino acid residue, N-(1–6C)alkylaminocarbonyl, N,N-di (1–6C)alkylaminocarbonyl, N-(1–6C)alkylaminoalkanoyl, N-(1–6C) alkanoylamino(1–6C)alkanonyl, C-hydroxyamino(1–6C)alkanoyl, hydroxy(2–6C)alkanoylamino(1–6C)alkanoyl, di(1–6C)alkylaminosulfonyl, hydrogen, hydroxyl, (1–6C)alkoxy, (1–6C)alkanoyloxy, (1–6C) alkyl, (2–6C)alkenyl (2–6C)alkynyl, (3–6C)alkenyloxycarbonyl, (1–6C)alkanoyl, amino(1–6C)alkyl, amido (CONH2), amino(1–6C)alkanoyl, aminocarbonyl (1–50) alkanoyl, hydroxy(1–6C) alkyl, carboxy, hydroxy(1–6C)alkanoyl, (1–6C)alkoxy(1–6C)alkanoyl, (1–6C)alkoxy(1–6C)alkyl, (1–6C)alkoxycarbonyl(1–5C)alkyl, (1–6C)alkoxycarbonyl, (1–6C)alkanoylamino, amino, halo, cyano, nitro, thiol, (1–6C) alkylthio, (1–6C)alkylsulfonyl, (1–6C)alkylsulphenyl or hydrazido;
- R3y represents R3 or a group of formula
- Rk-G2-Xa—
- in which G2 is absent or represents (1–3C)alkanediyl, Xa is absent or represents O, S, SO, SO2 NRL, CO, OCO, COO, CONRL, NRLCO, SO2NRL or NRLSO2;
- Rk represents a carbocyclic or heterocyclic group, optionally substituted by R3;
- and RL represents hydrogen or (1–6C)alkyl;
- R3z is oxo or is as defined for R3y, Xza is CR2 and Xz is O, S or NRz in which Rz has a value independently selected from a value for R3y;
- or a physiologically tolerable salt thereof.
17 more elements
3-(Aminomethyl)benzoyl-D/L-2ethylthiazol-4-ylglycine3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene-2amide or a physiologically tolerable salt thereof.
Dependencies are inferred from the claim text.